Solventum (SOLV) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and Solventum published the results on November 5, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. Solventum reports EPS two ways: GAAP, under the accounting rules every US filer follows, and adjusted diluted, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• Solventum sold its Purification and Filtration business in September 2025. The year-ago quarter includes $128 million of its sales and a $1,500 million gain on the sale, which is why year-ago GAAP EPS was $7.22.
• Solventum's July 2026 U.S. ERP deployment pulled about $125 million of customer orders into Q2 2026, which reversed in Q3 2026 and cut organic growth by about 630 basis points.

Source: Solventum Q3 2026 results, November 5, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How Solventum splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• Solventum's MedSurg revenue was $1.2 billion in Q3 2026, flat on $1.2 billion in Q3 2025, 62% of total revenue.
• Solventum's Dental Solutions revenue was $317 million in Q3 2026, down 7% from $340 million in Q3 2025, 16% of total revenue.
• Solventum's Health Information Systems revenue was $356 million in Q3 2026, up 3% from $345 million in Q3 2025, 18% of total revenue.
• Solventum's All Other revenue was $64.0 million in Q3 2026, down 17% from $77.0 million in Q3 2025, 3% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, Solventum said:

“Increased organic sales growth range toward the high end of +2.5% to +3.0% (toward the high end of +3.5% to +4.0% excluding ~100 bps of SKU exit impact)”

“Increased adjusted EPS range to $7.20 to $7.30; from prior range of $7.10 to $7.20”

“Affirming free cash flow in the range of $200 million to $300 million”

Source: Solventum Q3 2026 release, Nov 5, 2026.

This is the company's own guidance as of Nov 5, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the SOLV forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

GAAP net sales and diluted EPS, each as first reported in that quarter's release. Q3 2025 EPS includes the gain on the sale of the Purification and Filtration business.

We do not hold a confirmed date for Solventum's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Nov 5, 2026

Solventum, the health care business 3M spun off, reports three segments. MedSurg brought in $1,211 million of the $1,949 million total in Q3 2026, split between Infection Prevention and Surgical Solutions ($683 million) and Advanced Wound Care ($528 million). Health Information Systems added $356 million, Dental Solutions $317 million and All Other $64 million. (Solventum Q3 2026 release, Nov 5, 2026; Solventum Form 10-Q, Q3 2026, Nov 5, 2026)

Solventum's reported sales fell 7.0% and organic sales 2.8%. The gap is the September 2025 sale of the Purification and Filtration business, which had $128 million of sales a year earlier. The organic decline came from Solventum's July 2026 U.S. ERP deployment: customers ordered about $125 million early in Q2 2026 and then ran down that inventory in Q3, which Solventum put at a 630 basis point impact. (Solventum Q3 2026 release, Nov 5, 2026; Solventum Form 10-Q, Q3 2026, Nov 5, 2026)

By segment, Advanced Wound Care grew 8.9% reported and 1.5% organically, helped by the December 2025 acquisition of Acera Surgical. Infection Prevention and Surgical Solutions fell 5.7% organically and Dental Solutions 7.4%, the two businesses where the 10-Q says the ERP order reversal hit U.S. sales. Health Information Systems grew 4.4% organically. (Solventum Q3 2026 release, Nov 5, 2026; Solventum Form 10-Q, Q3 2026, Nov 5, 2026)

The United States was $1,131 million, or 58.0%, of Solventum's Q3 2026 sales, with organic growth of (4.2)%, and international sales were $818 million, or 42.0%. No customer accounted for more than 10% of revenue in 2025. On August 5, 2026 Solventum said it intends to pursue a separation of the Health Information Systems business. (Solventum Form 10-Q, Q3 2026, Nov 5, 2026; Solventum Form 10-K, 2025, Feb 27, 2026)

Solventum's GAAP diluted EPS was $(0.07) in Q3 2026 on a net loss of $12 million, while adjusted diluted EPS was $1.45, against $1.50. The adjustments are large: 3M spin-off and separation-related costs added $0.75 a share, amortization of acquisition-related intangibles $0.44, restructuring costs $0.22, acquisition and divestiture-related items $0.08 and certain litigation costs $0.03. (Solventum Q3 2026 release, Nov 5, 2026)

Year-ago GAAP EPS of $7.22 included a $(7.16) per share adjustment for the gain on the Purification and Filtration sale. Restructuring in Q3 2026, primarily under Solventum's Transform for the Future program, was $50 million before tax. The GAAP effective tax rate was (6.5)%, against 16.4%, and 19.3% on an adjusted basis. (Solventum Q3 2026 release, Nov 5, 2026; Solventum Form 10-Q, Q3 2026, Nov 5, 2026)

Diluted weighted average shares were 170.8 million, against 175.4 million. Under a $1 billion program approved in November 2025, Solventum repurchased 0.6 million shares for about $48 million in Q3 2026 and 5.3 million shares for about $403 million over nine months. (Solventum Q3 2026 release, Nov 5, 2026; Solventum Form 10-Q, Q3 2026, Nov 5, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

Solventum guides full-year organic sales growth, adjusted EPS and free cash flow in its release. With Q3 2026 results it said organic growth would be toward the high end of +2.5% to +3.0% (+3.5% to +4.0% excluding about 100 bps of SKU exits), raised adjusted EPS guidance to $7.20 to $7.30 from $7.10 to $7.20, and affirmed free cash flow of $200 million to $300 million. It does not guide GAAP EPS or reported sales. (Solventum Q3 2026 release, Nov 5, 2026)

A consensus figure is the average of the models published by the analysts who cover Solventum, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones Solventum's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning SOLV is on is SOLV a buy or a sell?, what analysts expect next is on the SOLV forecast, and what the company does is on the Solventum (SOLV) stock page.

Every number on this page can be traced to a document Solventum published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.